The POD1UM-303 trial demonstrated a median PFS of 9.3 months for retifanlimab plus chemotherapy versus 7.4 months for chemotherapy alone. In a disease with few first-line options, how significant is this improvement in clinical practice, especially considering historical benchmarks for SCAC?

Although the OS benefit at interim analysis—29.2 vs. 23.0 months—did not reach statistical significance, the six-month difference is clinically notable. How should oncologists interpret this finding in light of ongoing survival follow-up, and what thresholds might the final analysis need to cross to confirm benefit?

he study showed consistent PFS benefits across predefined subgroups. Given the heterogeneity in SCAC patient profiles—especially with HIV co-infection—how important is this finding for building clinician confidence in widespread use?

Median duration of response nearly doubled from 7.2 to 14 months with the addition of retifanlimab. What might this suggest about the synergy between PD-1 blockade and platinum-doublet chemotherapy in driving sustained tumor control?

Grade ≥3 adverse events were more frequent with retifanlimab, particularly neutropenia and anemia. From a safety management perspective, are these trade-offs justifiable in frontline therapy, and how does the tolerability compare with PD-1 regimens in other tumor types?

Zynyz received FDA approval both as part of a combination and as a monotherapy for post-platinum settings. How might this dual approval influence treatment sequencing and accessibility for SCAC patients, especially in resource-constrained oncology practices?

Considering that up to 90% of SCAC is HPV-driven and HIV increases risk dramatically, how well does the POD1UM-303 population reflect real-world epidemiology, and were immune-related outcomes influenced by patient immunocompetence?

Given these results and the momentum around checkpoint inhibitors in rare GI cancers, what do you foresee as the role of retifanlimab or similar agents in other HPV-associated lower GI malignancies—or even in broader HPV-positive tumor programs?